The research group "Pharmacogenomics and Individualized Pharmacotherapy" of Prof. Dr. med. Julia Stingl at the Federal Institute of Drugs and Medical Devices (BfArM) focusses on the variability of drug effects within patients as a reason of congenital and genetic differences. Within the StemCellFactory III project the BfArM targets the investigation of iPS derived neuronal cells and contribute to a better comprehension of local drug related effects within the brain, their toxicity as well as local degradation processes. These in vitro cell models are systematically evaluated by genotyping, gene expression analysis, pharmacogenetic profiling, enzyme kinetic calculations and tandem mass spectrometry. The obtained results should allow the optimization of modern and personalized medicine and lead to improvements for drug safety.
Univ.-Prof. Dr. med. Julia Stingl
Head of the Research Group Pharmacogenomics
Bundesinstitut für Arzneimittel und Medizinprodukte